chemomab.com - CMMB Short-Term Debt to Capital

Chemomab Therapeutics (CMMB) aims to expand its CM-101 antibody portfolio to combat rare fibrosis, confirming a market trend where the indicator stands at 0.00. Business protection relies on patents, although establishing a sustainable advantage requires long-term research. The core of its operations lies in the development of unique drugs capable of halting scarring in liver and lung organs, offering patients an exceptional treatment method.

This ratio reflects the share of short-term borrowings (up to one year) within the equity structure, allowing for an assessment of the issuer's dependence on operational lending. This chart of short-term liabilities to equity confirms the financial stability of Chemomab Therapeutics (CMMB), as full laboratory capacity and the absence of technical downtime minimize the need for emergency liquidity to support clinical trials.